Mesoblast Ltd has released a press release.
Increased Survival Using MSB Cells In Children With aGVHD
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Story so far
Earlier from Mesoblast
- Half Yearly Report and Accounts (including Appendix 4D)
- MSB Therapy Shows Benefit In First Cohort Of RA Patients
- Phase 3 Heart Failure Trial Size Substantially Reduced
- US Govt Grants for Further Development of Stem Cell Products
- USA FDA Clears Phase 2 Trial For Cervical Spinal Fusion
Later from Mesoblast
- GVHD Product Launched In Japan
- Key US Patent Granted For Treatment Of Rheumatoid Arthritis
- Circulation Publishes Improved Outcomes with Mesoblast Cells
- Mesoblast Receives $5.05m for Stem Cell Pipeline Development
- MSB Accelerates Plans for Commercial Manufacturing Operation
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast